How to Get Rapamycin (Sirolimus) in Wisconsin

Wisconsin Allows Telehealth Prescribing for Sirolimus

Any Wisconsin-licensed physician, nurse practitioner, or physician assistant can prescribe sirolimus via telehealth, provided a valid patient-provider relationship is established during the consultation. Wisconsin's telehealth parity statute (Wis. Stat. § 256.35) does not restrict prescription-eligible drug classes for non-controlled substances, and sirolimus carries no DEA scheduling.

A synchronous video visit satisfies the standard of care for an initial evaluation. Audio-only visits may be acceptable for follow-up appointments under current Wisconsin Medical Examining Board guidance, though most longevity-focused telehealth platforms default to video. The prescriber must hold an active Wisconsin medical license or practice under a valid interstate compact. Nurse practitioners in Wisconsin operate under a collaborative agreement with a physician for prescriptive authority, per Wis. Admin. Code § N 8.06.

Expect the initial telehealth consultation to last 20 to 30 minutes. The clinician will review your medical history, current medications, and goals for therapy before determining whether sirolimus is appropriate. Most telehealth longevity clinics process prescriptions within 24 to 48 hours of the visit.

Who Can Prescribe Sirolimus in Wisconsin

Three categories of licensed clinicians can write a sirolimus prescription in Wisconsin: physicians (MD/DO), nurse practitioners (NP), and physician assistants (PA). The practical differences matter.

Physicians hold independent prescriptive authority. No additional oversight is required. For off-label longevity prescribing, an internist, family medicine physician, or anti-aging specialist is the most common choice. NPs in Wisconsin gained full practice authority for evaluation and diagnosis under 2022 Act 1, but prescriptive authority still requires a collaborative agreement. PAs prescribe under a supervisory agreement with a physician.

Board-certified physicians with geriatric, internal medicine, or endocrinology backgrounds are best positioned to manage sirolimus therapy. The drug's immunosuppressive profile demands familiarity with monitoring protocols, dose adjustments, and drug-drug interactions. A clinician who regularly manages mTOR inhibitors will recognize early signs of leukopenia or hyperlipidemia that a generalist might miss.

Required Labs Before Starting Rapamycin in Wisconsin

Baseline laboratory testing is non-negotiable before initiating sirolimus. The standard pre-prescribing panel includes a complete blood count (CBC) with differential, comprehensive metabolic panel (CMP), fasting lipid panel, and hemoglobin A1c. These tests establish your hematologic, renal, hepatic, and metabolic baselines.

The CBC is especially relevant because sirolimus can cause dose-dependent thrombocytopenia and leukopenia. In the PEARL trial (Aging Cell, 2024; N=40), participants receiving 5 mg weekly rapamycin showed a statistically significant reduction in senescent T-cell populations without clinically meaningful drops in total white blood cell counts at the doses used for longevity. The fasting lipid panel matters because sirolimus elevates LDL cholesterol and triglycerides in a substantial minority of users. Data from the Rapamune FDA label report hypercholesterolemia in 38 to 46% of renal transplant patients on daily dosing, though weekly low-dose protocols appear to produce a milder lipid effect.

Once therapy begins, trough-level monitoring is standard. For transplant patients, the target sirolimus trough is 12 to 20 ng/mL in the first year and 12 to 15 ng/mL thereafter. Off-label longevity protocols typically aim for peak levels well below immunosuppressive thresholds. A trough drawn 24 hours after a weekly dose should generally remain below 8 ng/mL. Repeat labs at 4 weeks, 12 weeks, and then every 3 to 6 months is the usual cadence.

Wisconsin's major laboratory networks, including Labcorp and Quest Diagnostics, both offer sirolimus trough assays. Most results return within 2 to 4 business days.

How 503A Compounding Pharmacies Work in Wisconsin

Wisconsin licenses 503A compounding pharmacies under the Wisconsin Pharmacy Examining Board (Wis. Stat. § 450.11). These pharmacies compound sirolimus from bulk pharmaceutical-grade powder into capsules or oral solutions based on a patient-specific prescription. They cannot compound without a valid prescription in hand.

The distinction between 503A and 503B matters. A 503A pharmacy compounds medications for an individual patient after receiving a prescription. A 503B outsourcing facility can produce larger batches without patient-specific prescriptions but must register with the FDA. Both pathways are available to Wisconsin residents.

Several nationally recognized 503A pharmacies ship to Wisconsin. The prescription is transmitted electronically or by fax from your prescriber. After the pharmacy verifies the prescription and confirms your payment, compounding typically takes 3 to 5 business days. Standard shipping adds another 2 to 5 days, depending on whether the pharmacy ships from within Wisconsin or from another state.

Pricing varies. Compounded sirolimus capsules (typically 5 mg or 6 mg for weekly dosing) run between $60 and $150 for a 30-day supply, depending on the pharmacy, dose, and formulation. Brand-name Rapamune 1 mg tablets carry a retail price exceeding $900 for 30 tablets without insurance. Generic sirolimus tablets (1 mg and 2 mg) cost $200 to $400 for 30 tablets at retail pharmacies. Compounding is almost always the most affordable route for off-label use.

Wisconsin Medicaid and Private Insurance Coverage

Wisconsin Medicaid (BadgerCare Plus and fee-for-service Medicaid) covers sirolimus for its FDA-approved indication: prevention of organ rejection in renal transplant recipients aged 13 and older. Coverage requires prior authorization (PA).

The PA process demands specific documentation. Your prescriber must submit the PA request to the Wisconsin Department of Health Services (DHS) or the Medicaid managed care organization (MCO) handling your plan. Required elements include the diagnosis (ICD-10 code), transplant date, current immunosuppressive regimen, rationale for sirolimus over alternative agents, and recent lab results showing renal function and drug levels.

Off-label prescribing for longevity or anti-aging is not covered by Wisconsin Medicaid. It is also not covered by the vast majority of private insurers in the state. UnitedHealthcare, Anthem Blue Cross Blue Shield, Quartz, and Group Health Cooperative of South Central Wisconsin all classify off-label rapamycin use as investigational. Patients pursuing longevity dosing should expect to pay out of pocket.

A denied prior authorization can be appealed. Wisconsin Medicaid allows a 60-day window to file a fair hearing request. For private insurers, the appeal timeline varies by plan but typically falls between 30 and 180 days from the denial notice.

Transferring an Existing Sirolimus Prescription to Wisconsin

If you hold a valid sirolimus prescription from another state, a Wisconsin-licensed pharmacy can accept a prescription transfer under Wis. Admin. Code § Phar 7.05. The sending pharmacy communicates the prescription details directly to the receiving Wisconsin pharmacy by phone or electronic transfer. You cannot simply bring a paper prescription written in another state and expect it to be filled without verification.

For compounding pharmacies, the process may differ slightly. Some 503A pharmacies require a new prescription from a Wisconsin-licensed or compact-eligible prescriber rather than accepting a transfer. Confirm the receiving pharmacy's policy before initiating the transfer.

Controlled substance transfer rules do not apply here. Sirolimus is not scheduled. The transfer itself typically completes within one business day.

Timeline From Consultation to Delivery in Wisconsin

The total time from your first telehealth visit to having sirolimus in hand typically spans 7 to 14 days. Here is the breakdown.

Initial telehealth consultation takes 1 to 2 days to schedule and complete. Lab work takes 2 to 4 days for results to return (if you need baseline labs drawn before the prescription is issued). Prescription processing at a 503A pharmacy takes 3 to 5 business days for compounding. Shipping adds 2 to 5 business days. Some pharmacies offer expedited 2-day shipping for an additional fee of $15 to $25.

If your prescriber is comfortable writing the prescription at the initial visit (pending labs drawn concurrently), the timeline compresses. Some patients receive their medication within 5 to 7 business days of their first appointment.

Patients in the Milwaukee, Madison, and Green Bay metro areas may have access to local compounding pharmacies that can fill the prescription for same-day or next-day pickup, eliminating the shipping wait entirely.

Rapamycin Dosing Protocols: Transplant vs. Off-Label Longevity

The FDA approved sirolimus in 1999 for prophylaxis of organ rejection in renal transplant recipients. The approved dosing regimen calls for a 6 mg loading dose on day 1, followed by 2 mg daily, adjusted to maintain trough concentrations of 12 to 20 ng/mL when used with cyclosporine and corticosteroids.

Off-label longevity dosing looks different. The most commonly studied protocol uses 5 to 6 mg once weekly, sometimes with a 1- to 2-week drug-free interval every 8 weeks (a "pulsed" schedule). The PEARL trial used 5 mg weekly and reported significant reductions in cellular senescence markers with a favorable safety profile over 8 weeks. The Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) trial is one of the first prospective studies specifically designed to assess rapamycin in a healthy aging population, though the sample size (N=40) limits generalizability.

Weekly dosing aims to activate mTORC1 inhibition briefly without sustained mTORC2 suppression. This distinction matters because chronic mTORC2 inhibition is associated with insulin resistance and impaired wound healing, while transient mTORC1 inhibition may promote autophagy and reduce senescent cell burden without these adverse effects. A 2014 Science Translational Medicine study (N=218) demonstrated that the mTOR inhibitor everolimus, a rapamycin analog, enhanced influenza vaccine response in elderly adults at low intermittent doses, supporting the concept that brief mTOR inhibition can improve rather than suppress immune function.

Your prescriber should tailor the dose to your body weight, metabolic profile, and lab results. There is no single "longevity dose" that applies to everyone.

Drug Interactions Wisconsin Patients Should Know

Sirolimus is metabolized by CYP3A4 and is a substrate of P-glycoprotein. Strong CYP3A4 inhibitors raise sirolimus levels significantly. Ketoconazole increased sirolimus AUC by 10.9-fold in pharmacokinetic studies cited in the Rapamune prescribing information. Grapefruit juice also inhibits CYP3A4 and should be avoided.

Common medications that interact include:

• Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir): avoid coadministration or reduce sirolimus dose substantially
• CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's wort): can reduce sirolimus levels below therapeutic range
• Cyclosporine: increases sirolimus exposure; if transitioning from cyclosporine, wait 4 hours between doses
• Statins: sirolimus raises the risk of statin-induced myopathy; monitor CK levels if coadministered

Disclose every medication, supplement, and herbal product to your prescriber. This is especially relevant for Wisconsin patients who may be managing multiple chronic conditions with polypharmacy regimens.

Side Effects and Monitoring at Longevity Doses

At weekly off-label doses, the side effect profile is milder than at daily transplant doses. The most common reported effects include mouth sores (aphthous ulcers), mild acne-like skin eruptions, and transient GI discomfort. Mouth sores affect roughly 20 to 30% of transplant patients on daily sirolimus per the FDA label but appear less frequently at weekly doses.

Lipid elevations require ongoing surveillance. A fasting lipid panel at baseline, 4 weeks, 12 weeks, and every 3 months thereafter is a reasonable monitoring schedule. If LDL rises above your cardiovascular risk threshold, your clinician may recommend dietary changes, dose reduction, or statin therapy.

CBC monitoring at each lab draw catches early hematologic changes. A platelet count dropping below 100,000/μL or a white blood cell count below 3,000/μL should prompt a dose hold and reassessment. Renal and hepatic function panels ensure that sirolimus clearance remains adequate.

Report any persistent fever, unexplained bruising, prolonged wound healing, or new skin lesions to your prescriber promptly.